Test Price
2,800 AEDโ Home Collection Available
KLF8 Gene Non-Syndromic Intellectual Disability Genetic Test
Executive Summary & Core Metrics
DHA-APPROVED Executive Summary
- โ Diagnostic Accuracy Guarantee: 99.9% Analytical Sensitivity & Specificity via ISO 9001:2015 Certified NGS Processing.
- โ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM โ 11 PM Daily).
- โ Clinical Guidance: Telephonic Post-Test Clinical Correlation & Result Interpretation by DHA-Licensed Genetic Consultants.
- โ Insurance & Billing: Direct Billing Verification via WhatsApp.
- ๐ Immediate Support: +971 54 548 8731
Test Overview & Methodology
The KLF8 Gene Non-Syndromic Intellectual Disability Genetic Test is a high-resolution molecular diagnostic assay designed to detect pathogenic variants in the KLF8 gene (Krรผppel-Like Factor 8) associated with autosomal non-syndromic intellectual disability. This test utilises Next Generation Sequencing (NGS) technology to deliver comprehensive coding-region coverage with unparalleled nucleotide-level resolution.
| Parameter | Our KLF8 NGS Test | Closest Alternative (Conventional Sanger Sequencing) |
|---|---|---|
| Precision | >99.9% Single-Nucleotide Resolution (NGS) | ~98% Targeted Exon-Only Coverage |
| Methodology | Next Generation Sequencing (NGS) โ High-Throughput Parallel Sequencing | Sanger Sequencing (Low Throughput, Single Amplicon) |
| Turnaround Time | 21โ28 Working Days (Comprehensive Bioinformatic Analysis) | 14โ21 Days (Limited Analytical Depth) |
| Coverage | Full Gene: Coding Exons, Splice Junctions, UTR Regions | Selected Exons Only |
| Clinical Reporting | ACMG/AMP Guidelines (Latest Version) + Clinical Correlation Note | Basic Variant Call Without Clinical Context |
Physician Insight & Safety Protocols
Clinical Note from Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403):
"The KLF8 NGS test provides crucial molecular insight into the aetiology of non-syndromic intellectual disability. However, interpretation must always integrate detailed family history, developmental assessment, and neuroimaging findings. I strongly recommend pre-test genetic counselling to set expectations and post-test counselling to translate results into actionable clinical management. A negative result does not rule out other genetic or environmental causes; comprehensive evaluation remains essential."
Medication Advisory Notice
Do not discontinue, adjust, or alter any prescribed medication, anticonvulsant, or neurodevelopmental therapy without consulting your treating physician. This genetic test is diagnostic in nature and does not provide pharmacogenomic guidance for medication management. Any change in treatment must be supervised by your DHA-licensed neurologist or paediatrician.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Individuals unable to provide informed consent (or lacking a legal guardian per UAE Federal Law No. 2 of 2019). Mandatory genetic counselling session required before sample collection.
- Exclusion: Samples received without completed Clinical History & Pedigree Chart documentation as mandated by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Exclusion: Degraded, haemolysed, or improperly stored DNA specimens. Only whole blood in EDTA vacutainers, FTA card dried blood spots, or previously extracted high-quality DNA (A260/A280 ratio 1.8โ2.0) are accepted.
- ER Red Flag: If the patient experiences acute neurological deterioration, seizures, or loss of consciousness, proceed immediately to the nearest DHA-licensed Emergency Department. Do not wait for genetic test results.
- ER Red Flag: Test results indicating a pathogenic KLF8 variant should prompt urgent referral to a Clinical Geneticist and Paediatric Neurologist for multidisciplinary management โ this does not constitute a medical emergency but requires timely specialist intervention.
Patient FAQ & Clinical Guidance
1. What does the KLF8 Genetic Test diagnose, and who should consider it?
This test identifies pathogenic mutations in the KLF8 gene linked to autosomal non-syndromic intellectual disability. It is clinically indicated for individuals with unexplained global developmental delay or moderate-to-severe intellectual disability without dysmorphic features, and for carrier screening in consanguineous families. A DHA-licensed geneticist or neurologist should order the test after comprehensive evaluation.
2. How is the sample collected, and what preparation is required?
Sample collection options include whole blood in EDTA vacutainers, dried blood spots on FTA cards, or previously extracted high-quality genomic DNA. No fasting or medication adjustment is necessary. Pre-test genetic counselling and a three-generation pedigree chart are mandatory. Our ISO-certified mobile phlebotomy service operates daily from 8 AM to 11 PM across all seven Emirates.
3. How reliable are the results, and what happens after I receive them?
Results are >99.9% analytically accurate with ACMG/AMP variant classification. Each report includes variant details, zygosity, clinical interpretation, and cascade screening recommendations. Within 48 hours of report release, a DHA-licensed genetic counsellor provides a telephonic session to discuss findings and guide next steps. All genomic data is protected under UAE PDPL with end-to-end encryption.
UAE Regulatory & Data Privacy Adherence
UAE Regulatory Compliance & Accreditation
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All genomic data is classified as sensitive personal data; stored, processed, and transferred in full compliance with UAE federal data sovereignty requirements.
- Federal Law No. 2 of 2019: Health information and clinical data are handled under this law concerning the use of ICT in health fields.
- ISO 9001:2015 Certification: Facility License No. 1143 | ISO Cert: INT/EGQ/2509DA/3139 โ quality management systems in medical laboratory operations.
- DHA Facility License: 1143 โ Dubai Health Authority licensed diagnostic facility.
Clinical & Logistical Metadata
| Test Name | KLF8 Gene Non-Syndromic Intellectual Disability Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21โ28 Working Days |
| Sample Type / Matrix | Whole Blood (EDTA), Dried Blood Spot (FTA Card), or High-Quality Extracted Genomic DNA |
| Methodology Used | Next Generation Sequencing (NGS) โ Full Gene Coding Regions, Splice Junctions, UTRs |
| ICD-10-CM Code | F79 |
| LOINC Code | 48018-3 |
| DHA Facility License & Laboratory Address | Facility License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians